In vitro antiproliferative and apoptosis-inducing properties of a mononuclear copper(II) complex with dppz ligand, in two genotypically different breast cancer cell lines.

In the background that there is concerted effort to discover newer metal-based cancer chemotherapeutic agents that could overcome the limitations in cisplatin and that copper, a biocompatible and redox-active metal, offers potential as alternative to cisplatin, the present study was undertaken to investigate the in vitro anti-proliferative properties of the mononuclear copper(II)complex [Cu(L)(diimine)] + where LH = 2-[(2-dimethylaminoethylimino)methyl]phenol and diimine = dipyrido[3,2-a:2',3'-c]phenazine (dppz) using breast cancer cell lines MCF-7 (ER(+ve) and p53(WT)) and MDA-MB-231(ER(-ve) and p53(mutant)) when cisplatin was used as positive control. The complex affected the viability of both the cell lines in dose-as well as duration-dependent manner as revealed in the MTT assay. The 24 and 48 h IC50 of the complex were several times lesser than those of cisplatin, and within this huge difference the efficacy of the complex was much superior with MCF-7 cell compared to MDA-MB-231 cell. The cell death was preferentially apoptosis, though necrosis also occurred to a certain extent. These inferences were substantiated by AO/EB fluorescent staining, Hoechst staining, assessment of mitochondrial transmembrane potential, comet assay for DNA damage, DCFH assay for reactive oxygen species (ROS) generation and Western blot of apoptosis-related proteins. Thus, the copper(II) dppz complex under investigation is much more efficient than cisplatin in affecting viability of the breast cancer cells. The underlying mechanism appears to be DNA damage-primed (in view of the known intercalation mode of binding of the complex with DNA) and ROS-associated mitochondria-mediated intrinsic apoptosis to a great extent but necrosis also has a role to a certain extent, which may also be a PARP-mediated cell death independent of apoptosis. Within the purview of this conclusion, the results indicate that the ER and/or p53 genotypes have a bearing on the efficacy of the complex as a cytotoxic agent since the response in the ER(-ve) and p53(mutant) MDA-MB-231 cell was not so prominent as in ER(+ve) and p53(WT) MCF-7 cell. Taken together, the complex has been shown to be a potential DNA damaging agent and, in the light of the superiority of the complex over cisplatin, we are further investigating the possibility of targeted nano-delivery of the complex to the tumor cells. When tested on a normal cell, 3T3, Cu(II)dppz was found to affect its viability but at concentrations very high compared to those for the breast cancer cells. Yet, this is a cause of concern and, therefore, we are working out a strategy for targeted delivery of this complex to the cancer cells only.

Fluorescent mixed ligand copper(II) complexes of anthracene-appended Schiff bases: studies on DNA binding, nuclease activity and cytotoxicity.

A series of mixed ligand copper(ii) complexes of the type [Cu(L)(phen)(ACN)](ClO4)21-5, where L is a bidentate Schiff base ligand (N(1)-(anthracen-10-ylmethylene)-N(2)-methylethane-1,2-diamine (L1), N(1)-(anthracen-10-ylmethylene)-N(2),N(2)-dimethylethane-1,2-diamine (L2), N(1)-(anthracen-10-yl-methylene)-N(2)-ethylethane-1,2-diamine (L3), N(1)-(anthracen-10-ylmethylene)-N(2),N(2)-diethylethane-1,2-diamine (L4) and N(1)-(anthracen-10-ylmethylene)-N(3)-methylpropane-1,3-diamine (L5)) and phen is 1,10-phenanthroline, have been synthesized and characterized by spectral and analytical methods. The X-ray crystal structure of 5 reveals that the coordination geometry around Cu(ii) is square pyramidal distorted trigonal bipyramidal (τ, 0.76). The corners of the trigonal plane of the geometry are occupied by the N2 nitrogen atom of phen, the N4 nitrogen atom of L5 and the N5 nitrogen of acetonitrile while the N1 nitrogen of phen and the N3 nitrogen of L5 occupy the axial positions with an N1-Cu1-N3 bond angle of 176.0(3)°. All the complexes display a ligand field band (600-705 nm) and three less intense anthracene-based bands (345-395 nm) in solution. The Kb values calculated from absorption spectral titration of the complexes (π→π*, 250-265 nm) with Calf Thymus (CT) DNA vary in the order 5 > 4 > 3 > 2 > 1. The fluorescence intensity of the complexes (520-525 nm) decreases upon incremental addition of CT DNA, which reveals the involvement of phen rather than the appended anthracene ring in partial DNA intercalation with the DNA base stack. The extent of quenching is in agreement with the DNA binding affinities and the relative increase in the viscosity of DNA upon binding to the complexes as well. Thus 5 interacts with DNA more strongly than 4 on account of the stronger involvement in hydrophobic DNA interaction of the anthracenyl moiety, which is facilitated by the propylene ligand backbone with chair conformation. The ability of complexes (100 µM) to cleave DNA (pUC19 DNA) in 5 mM Tris-HCl/50 mM NaCl buffer at pH 7.1 in the absence of a reducing agent or light varies in the order 5 > 4 > 3 > 2 > 1, which is in conformity with their DNA binding affinities. Interestingly, cytotoxicity studies on the MCF-7 human breast cancer cell line show that the IC50 value of 5 is less than that of cisplatin for the same cell line, revealing that it can act as an effective cytotoxic drug in a time-dependent manner.

Efficient DNA cleavage mediated by mononuclear mixed ligand copper(II) phenolate complexes: the role of co-ligand planarity on DNA binding and cleavage and anticancer activity.

The new mononuclear copper(II) complexes [Cu(L)(H(2)O)(2)](+)1 and [Cu(L)(diimine)](+)2-6, where LH=2-[(2-dimethylaminoethylimino)methyl]phenol and diimine=2,2'-bipyridine (bpy) (2), or 1,10-phenanthroline (phen) (3), or dipyrido[3,2-f:2',3'-h]quinoxaline (dpq) (4) or dipyrido[3,2-a:2',3'-c]phenazine (dppz) (5) or 11,12-dimethyldipyrido[3,2-a:2',3'-c]phenazine (dmdppz) (6), have been isolated and characterized. The X-ray crystal structures of 2 contains the monomeric complex molecule with a trigonal bipyramidal distorted square pyramidal (TBPDSP) coordination geometry, while 4 and 6 with square pyramidal distorted trigonal bipyramidal (SPDTBP) coordination geometry. The amine nitrogen of -NMe(2) group of the tridentate primary ligand is located at one of the corners of the square plane in 2 and 6 but in the axial position in 4. The interaction of the complexes with calf thymus DNA has been investigated using UV-visible and fluorescence spectroscopy, and viscosity measurements to understand the effect of diimine co-ligands on the mode and extent of DNA binding. The complexes 4 and 5 interact with calf thymus DNA more strongly than the other complexes through partial intercalation of the extended planar ring of the dpq (4) and dppz (5) co-ligands with the DNA base stack. All the complexes, except 1, effect the double strand DNA cleavage of plasmid DNA and 5 cleaves plasmid DNA in the absence of a reductant at a concentration (40 µM) lower than 4. It is remarkable that all the complexes display cytotoxicity against human breast cancer cell lines (MCF-7) and human cervical epidermoid carcinoma cell lines (ME 180) with potency higher than the currently used chemotherapeutic agent cisplatin and that 5 exhibits cytotoxicity higher than the other complexes.